NYSE:AZN - AstraZeneca Stock Price, Price Target & More

$35.30 +0.01 (+0.03 %)

(As of 04/27/2018 02:56 AM ET)

Previous Close$35.30

Today's Range$35.24 - $35.50

52-Week Range$28.43 - $36.75

Volume2.84 million shs

Average Volume4.10 million shs

Market Capitalization$88.96 billion

P/E Ratio8.25

Dividend Yield3.90%

Beta0.62

About AstraZeneca (NYSE:AZN)

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:AZN

CUSIPN/A

Webwww.astrazeneca.com

Phone44-0-20-3749-5000

Debt

Debt-to-Equity Ratio0.93%

Current Ratio0.80%

Quick Ratio0.62%

Price-To-Earnings

Trailing P/E Ratio8.25

Forward P/E Ratio20.76

P/E Growth1.87

Sales & Book Value

Annual Sales$22.47 billion

Price / Sales3.98

Cash Flow$3.3555 per share

Price / Cash10.52

Book Value$6.57 per share

Price / Book5.37

Profitability

EPS (Most Recent Fiscal Year)$4.28

Net Income$3.00 billion

Net Margins13.36%

Return on Equity34.74%

Return on Assets8.52%

Miscellaneous

Employees59,700

Outstanding Shares2,532,900,000

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semiannual dividend on Monday, February 5th. Investors of record on Friday, February 16th will be given a dividend of $0.95 per share on Monday, March 19th. This represents a yield of 5.62%. The ex-dividend date is Thursday, February 15th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca (NYSE:AZN) released its earnings results on Friday, February, 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.86. The business had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the business earned $1.21 earnings per share. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, May, 18th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca issued an update on its FY18 earnings guidance on Friday, February, 2nd. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.64.

What price target have analysts set for AZN?

18 Wall Street analysts have issued twelve-month price objectives for AstraZeneca's shares. Their predictions range from $35.00 to $42.00. On average, they anticipate AstraZeneca's stock price to reach $38.1167 in the next year. View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
Mr. Jefrey Pott, Gen. Counsel
Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Has AstraZeneca been receiving favorable news coverage?

News headlines about AZN stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AstraZeneca earned a news impact score of 0.02 on Accern's scale. They also assigned news articles about the company an impact score of 46.29 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $35.30.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $88.96 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]

MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		516 (Vote Outperform)
Underperform Votes:		890 (Vote Underperform)
Total Votes:		1,406

MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

AstraZeneca (NYSE:AZN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is $38.1167, suggesting that the stock has a possible upside of 7.98%. The high price target for AZN is $42.00 and the low price target for AZN is $35.00. There are currently 1 sell rating, 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.58	2.55	2.52
Ratings Breakdown:	1 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 10 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$38.1167	$36.3214	$35.0917	$35.7029
Price Target Upside:	7.98% upside	4.82% upside	2.93% downside	3.13% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/22/2018	BMO Capital Markets	Set Price Target	Buy	$40.00	Low
3/19/2018	Jefferies Group	Upgrade	Hold -> Buy	$28.43 -> $36.70	Low
2/6/2018	Leerink Swann	Boost Price Target	Market Perform -> Market Perform	$36.00 -> $38.00	Medium
2/5/2018	Sanford C. Bernstein	Boost Price Target	Outperform	$40.00 -> $42.00	High
12/29/2017	JPMorgan Chase	Upgrade	Neutral -> Overweight		Low
10/18/2017	Citigroup	Upgrade	Buy		N/A
10/17/2017	Cowen	Reiterated Rating	Hold	$37.00	N/A
10/16/2017	Credit Suisse Group	Upgrade	Neutral -> Outperform		N/A
9/25/2017	BNP Paribas	Upgrade	Neutral -> Outperform		Medium
9/14/2017	Liberum Capital	Downgrade	Buy -> Hold		Low
9/6/2017	Natixis	Upgrade	Neutral -> Buy		Low
9/1/2017	Argus	Reiterated Rating	Buy	$35.00	Low
8/9/2017	Investec	Upgrade	Hold -> Buy		Low
8/9/2017	Piper Jaffray	Reiterated Rating	Buy		Low
8/1/2017	Pareto Securities	Upgrade	Sell -> Hold		Low
7/28/2017	Morgan Stanley	Downgrade	Overweight -> Equal Weight		High
7/13/2017	Goldman Sachs	Reiterated Rating	Sell		High
7/13/2017	Barclays	Reiterated Rating	Overweight		High
4/5/2017	UBS	Downgrade	Buy -> Neutral	$35.44 -> $25.55	N/A
2/21/2017	Berenberg Bank	Reiterated Rating	Buy		N/A
11/11/2016	Deutsche Bank	Reiterated Rating	Buy		N/A
11/11/2016	Beaufort Securities	Reiterated Rating	Hold		N/A
11/10/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
11/10/2016	Bank of America	Reiterated Rating	Buy	$41.37	N/A
11/10/2016	Shore Capital	Reiterated Rating	Hold		N/A

(Data available from 4/27/2016 forward)

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Earnings Estimates

2018 EPS Consensus Estimate: $1.67

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.42	$0.42	$0.42
Q2 2018	1	$0.40	$0.40	$0.40
Q3 2018	1	$0.39	$0.39	$0.39
Q4 2018	1	$0.46	$0.46	$0.46

AstraZeneca (NYSE AZN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/18/2018		$0.28					N/A
2/2/2018	Q4 2017	$0.44	$1.30	$5.4936 billion	$5.7770 billion	View	Listen
11/9/2017	Q3	$0.57	$1.12	$5.9999 billion	$6.2320 billion	View	N/A
7/27/2017	6/30/2017	$0.41	$0.87	$5.0391 billion	$5.0510 billion	View	N/A
4/27/2017	3/31/2017	$0.38	$0.99	$5.4045 billion	$5.4050 billion	View	N/A
2/2/2017	Q416	$0.51	$1.21	$5.43 billion	$5.5850 billion	View	Listen
11/10/2016	Q316	$0.48	$1.32	$5.95 billion	$5.6990 billion	View	N/A
7/28/2016	Q216	$0.76	$0.83	$5.56 billion	$5.60 billion	View	Listen
4/29/2016	Q1	$0.5970	$0.51	$5.96 billion	$6.12 billion	View	Listen
2/4/2016	Q415	$0.88	$0.94	$6.27 billion	$6.40 billion	View	N/A
11/5/2015	Q315	$0.51	$1.03	$5.90 billion	$5.85 billion	View	N/A
7/30/2015	Q2	$0.52	$1.21	$6.0159 billion	$5.8360 billion	View	Listen
4/24/2015	Q1	$1.07	$1.08	$5.8724 billion	$6.0570 billion	View	N/A
2/5/2015	Q314	$0.85	$0.76	$6.68 billion	$6.6830 billion	View	N/A
11/6/2014	Q3	$1.04	$1.05	$6.4398 billion	$6.5420 billion	View	N/A
7/31/2014	Q214	$1.09	$1.30	$6.24 billion	$6.4540 billion	View	N/A
4/29/2014	Q114	$1.23	$1.17	$6.32 billion	$6.42 billion	View	N/A
2/6/2014	Q413	$1.22	$1.23	$6.91 billion	$3.84 billion	View	N/A
10/31/2013	Q313	$1.27	$1.21	$6.45 billion	$6.25 billion	View	N/A
8/1/2013	Q213	$1.16	$1.20	$6.24 billion	$6.23 billion	View	N/A
4/25/2013		$1.36	$1.41	$6.5431 billion	$6.3850 billion	View	N/A
1/31/2013	Q412	$1.37	$1.56	$7.17 billion	$7.2820 billion	View	N/A
10/25/2012		$1.44	$1.51			View	N/A
7/26/2012		$1.38	$1.53			View	N/A
4/26/2012		$1.73	$1.81			View	N/A
2/2/2012		$1.57	$1.61			View	N/A
10/27/2011		$1.64	$1.71			View	N/A
7/28/2011		$1.74	$1.53			View	N/A
4/27/2011	Q1 2011	$1.02	$1.04			View	N/A
1/27/2011	Q4 2010	$0.67	$0.68			View	N/A
10/27/2010	Q3 2010	$0.76	$0.54			View	N/A
7/30/2010	Q2 2010	$0.80	$0.73			View	N/A
4/29/2010	Q1 2010	$0.86	$1.02			View	N/A
10/29/2009	Q3 2009	$0.68	$0.73			View	N/A
7/30/2009	Q2 2009	$0.68	$0.82			View	N/A
1/29/2009	Q4 2008	$0.59	$0.63			View	N/A
4/24/2008	Q1 2008	$0.60	$0.52			View	N/A
1/31/2008	Q4 2007	$0.50	$0.52			View	N/A

(Earnings results data provided by Zacks Investment Research)

AstraZeneca (NYSE:AZN) Dividend Information

AstraZeneca pays an annual dividend of $1.37 per share, with a dividend yield of 3.88%. AZN's most recent semiannual dividend payment was Monday, March 19. AstraZeneca pays out 32.01% of its earnings out as a dividend.

Most Recent Dividend:	3/19/2018
Annual Dividend:	$1.37
Dividend Yield:	3.88%
Dividend Growth:	-21.20% (3 Year Average)
Payout Ratio:	32.01% (Trailing 12 Months of Earnings) 80.59% (Based on This Year's Estimates) 71.73% (Based on Next Year's Estimates)

Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2018	semiannual	$0.95	5.62%	2/15/2018	2/16/2018	3/19/2018
7/28/2017	None	$0.44	2.98%	8/9/2017	8/11/2017	9/11/2017
2/3/2017	semiannual	$0.95	6.81%	2/15/2017	2/17/2017	3/20/2017
7/29/2016		$0.44		8/10/2016	8/12/2016	9/12/2016
2/5/2016		$0.93		2/17/2016	2/19/2016	3/21/2016
2/10/2015	semiannual	$1.90	5.57%	2/18/2015	2/20/2015	3/23/2015
8/1/2014	semiannual	$0.90	2.48%	8/13/2014	8/15/2014	9/15/2014
2/10/2014	special	$1.90	2.79%	2/19/2014	2/21/2014	3/24/2014
8/2/2013	semiannual	$0.90	3.52%	8/14/2013	8/16/2013	9/16/2013
2/1/2013	special	$1.90	3.72%	2/13/2013	2/15/2013	3/18/2013

(Data available from 1/1/2013 forward)

AstraZeneca (NYSE AZN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 15.12%

Insider Trading History for AstraZeneca (NYSE:AZN)

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

AstraZeneca (NYSE AZN) News Headlines

Source:

Date	Headline
	Novo Nordisk’s Victoza Could See High Growth in 2018 finance.yahoo.com - April 26 at 8:13 AM
	BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer www.reuters.com - April 24 at 8:16 AM
	BRIEF-Redx Pharma Appoints Astrazeneca Executive Lisa Anson As CEO www.reuters.com - April 24 at 8:16 AM
	AstraZeneca: Cancer-drug combo stumbles in trial www.marketwatch.com - April 24 at 8:16 AM
	AstraZeneca flop a fresh blow to cancer immunotherapy combination finance.yahoo.com - April 24 at 8:16 AM
	AstraZeneca to raise stake in Circassia to up to 19.9 percent finance.yahoo.com - April 24 at 8:16 AM
	3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close seekingalpha.com - April 21 at 8:16 AM
	AstraZeneca (AZN) Downgraded by BidaskClub to Hold www.americanbankingnews.com - April 19 at 1:56 PM
	BRIEF-Astrazeneca says US FDA Approves Tagrisso As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung ... www.reuters.com - April 19 at 8:12 AM
	AstraZeneca cancer drug Tagrisso gets FDA approval www.marketwatch.com - April 19 at 8:12 AM
	AstraZeneca wins US approval for 1st-line use of lung cancer drug www.reuters.com - April 19 at 8:12 AM
	AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug finance.yahoo.com - April 19 at 8:12 AM
	US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer www.prnewswire.com - April 18 at 7:46 PM
	A new Highmark contract with a pharma company part of a growing trend in drug purchasing finance.yahoo.com - April 17 at 6:00 PM
	BRIEF-Highmark Inc Signs Outcomes-Based Agreement With Astrazeneca For Symbicort www.reuters.com - April 17 at 8:24 AM
	Highmark Inc. Signs Outcomes-Based Agreement with AstraZeneca for Symbicort www.prnewswire.com - April 17 at 8:24 AM
	An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued finance.yahoo.com - April 17 at 8:24 AM
	AstraZeneca (AZN) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - April 16 at 9:16 PM
	How Will This Unexpected War For First-Line Lung End? seekingalpha.com - April 16 at 8:12 AM
	BRIEF-AstraZeneca says Updated Overall Survival Data For Lynparza(Olaparib) In Gbrca-Mutated Her2-Negative ... www.reuters.com - April 16 at 8:12 AM
	BRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACR www.reuters.com - April 16 at 8:12 AM
	Jefferies Group Weighs in on AstraZeneca's FY2018 Earnings (AZN) www.americanbankingnews.com - April 16 at 2:31 AM
	AstraZeneca (AZN) Rating Reiterated by Cowen www.americanbankingnews.com - April 15 at 9:31 AM
	BRIEF-Molecular Partners To Cooperate With Astrazeneca On Ongoing Oncology Clinical Study www.reuters.com - April 13 at 8:16 AM
	Form 6-K ASTRAZENECA PLC For: Apr 13 www.streetinsider.com - April 13 at 8:16 AM
	Talend Connect 2018: New Speakers Include AstraZeneca, Royal Caribbean & TD Bank www.globenewswire.com - April 12 at 8:26 AM
	AstraZeneca (AZN) Rating Reiterated by Piper Jaffray www.americanbankingnews.com - April 11 at 7:53 PM
	How AstraZeneca’s 1Q18 Shook Out finance.yahoo.com - April 10 at 8:20 AM
	Zacks Investment Research Downgrades AstraZeneca (AZN) to Sell www.americanbankingnews.com - April 9 at 11:02 AM
	Ionis and AstraZeneca Advance New Drug for NASH www.prnewswire.com - April 9 at 8:14 AM
	AstraZeneca (AZN) Upgraded to "Outperform" at Credit Suisse Group www.americanbankingnews.com - April 7 at 12:26 PM
	Cowen Reiterates Hold Rating for AstraZeneca (AZN) www.americanbankingnews.com - April 7 at 12:03 AM
	Zacks: Analysts Anticipate AstraZeneca plc (AZN) to Post $0.46 Earnings Per Share www.americanbankingnews.com - April 6 at 10:09 AM
	Form 6-K ASTRAZENECA PLC For: Apr 05 www.streetinsider.com - April 5 at 10:05 AM
	AstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 5:39 PM
	PRESS DIGEST- Financial Times - April 4 finance.yahoo.com - April 4 at 8:16 AM
	FDA accepts AstraZeneca's application for moxetumomab pasudotox seekingalpha.com - April 3 at 8:17 AM
	AstraZeneca: FDA Grants Moxetumomab Pasudotox BLA Priority Review www.nasdaq.com - April 3 at 8:17 AM
	AstraZeneca: FDA Approves BYDUREON For Expanded Use - Quick Facts www.nasdaq.com - April 3 at 8:17 AM
	AstraZeneca, Merck: European Medicines Agency To Review MAA For Lynparza www.nasdaq.com - April 3 at 8:17 AM
	AstraZeneca cancer drugs cross EU, US hurdles www.marketwatch.com - April 3 at 8:17 AM
	US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia finance.yahoo.com - April 3 at 8:17 AM
	US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control finance.yahoo.com - April 3 at 8:17 AM
	Compugen inks antibody development deal with AstraZeneca; shares ahead 11% premarket seekingalpha.com - April 2 at 8:33 AM
	Compugen, AstraZeneca unit in cancer drug development deal finance.yahoo.com - April 2 at 8:33 AM
	AstraZeneca (AZN) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - March 30 at 11:10 PM
	AstraZeneca (AZN) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - March 29 at 12:44 PM
	AstraZeneca's Symbicort ([budesonide + formoterol]) Drug Analysis Report 2018 - ResearchAndMarkets.com www.businesswire.com - March 29 at 8:21 AM
	AstraZeneca (AZN) Given a $38.00 Price Target at BMO Capital Markets www.americanbankingnews.com - March 28 at 8:42 PM
	ValuEngine Downgrades AstraZeneca (AZN) to Buy www.americanbankingnews.com - March 24 at 1:56 PM

AstraZeneca (NYSE:AZN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

AstraZeneca (NYSE AZN) Stock Chart for Friday, April, 27, 2018

Loading chart…

This page was last updated on 4/27/2018 by MarketBeat.com Staff